4
Clinical Trials associated with Insulin lispro biosimilar (Diasome Pharmaceuticals, Inc.)A Phase 2b Randomized, Double-blind Trial Comparing HDV-Insulin Lispro Versus Insulin Lispro Alone in Adults With Type 1 Diabetes Receiving Insulin Degludec
The goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in Type 1 diabetes patients. Participants will use continuous glucose monitoring to measure the sugar levels in their blood, and work with the doctor to find the best doses. One group of patients will get the liver targeting insulin, and the other group will use insulin they normally use for treating Type 1 diabetes. The participant will be part of the study for up to 32 weeks.
An Exploratory Randomized Open-Label 2-Arm Comparison of Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec to Determine Optimum Basal Insulin Dosing Regimens in Type 1 Diabetes Mellitus Subjects
Multi-center, open-label, multiple dose safety, tolerability and efficacy study
A Randomized Controlled Trial Comparing 21 Days of Continuous Subcutaneous Insulin Infusion (CSII) Using Hepatic Directed Vesicle (HDV) Insulin to Standard CSII in Type 1 Diabetes Mellitus
Single Center, Double Blind, Active Comparator Controlled 2-Way Crossover Multiple Dose Safety, Tolerability and Efficacy Study
100 Clinical Results associated with Insulin lispro biosimilar (Diasome Pharmaceuticals, Inc.)
100 Translational Medicine associated with Insulin lispro biosimilar (Diasome Pharmaceuticals, Inc.)
100 Patents (Medical) associated with Insulin lispro biosimilar (Diasome Pharmaceuticals, Inc.)
100 Deals associated with Insulin lispro biosimilar (Diasome Pharmaceuticals, Inc.)